Trial Profile
A Randomized, Multicenter Phase II Study of Panitumumab Plus FOLFIRI With or Without Hepatic Arterial Infusion as Second-Line Treatment in Patients With Wild Type RAS Who Have Unresectable Hepatic Metastases From Colorectal Cancer
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase II
Latest Information Update: 05 Nov 2021
Price :
$35
*
At a glance
- Drugs Panitumumab (Primary) ; Dexamethasone; Floxuridine; Fluorouracil; Fluorouracil; Folinic acid; Irinotecan
- Indications Adenocarcinoma; Colorectal cancer; Liver cancer
- Focus Therapeutic Use
- 17 May 2019 Status changed to withdrawn prior to enrolment.
- 17 May 2019 Planned End Date changed from 1 Feb 2020 to 16 May 2019.
- 17 May 2019 Planned primary completion date changed from 1 Feb 2020 to 16 May 2019.